Over 23,000 studies tout the benefits of medical cannabis for people facing everything from Alzheimer’s disease to to chronic pain to diabetes, and cannabis is becoming mainstream. Backed by an enormous body of scientific research, ever more progressive cannabis laws, and enthusiastic public opinion, cannabis is earning the reputation it deserves as a groundbreaking health solution.
Learn more about how we’re harnessing this rapidly expanding industry and making medical cannabis available to families all over the world.
More than 1.2 million people already use medical marijuana for a wide variety of medical problems, from cancer to epilepsy to depression. If you’re not sure how the industry is shifting, consider these statistics:
The estimated size of the legal U.S. marijuana industry (both medical and recreational) in 2016 – a boost of more than 25% over the year 2015. This substantial increase is linked to massive growth in Colorado, Washington, Oregon and other states expected to approve both medical and recreational use.
The percentage of Americans who support the legalization of marijuana for medical treatment if prescribed by a doctor. In 2011, 74% did. Attitudes toward marijuana continue to shift, with the public becoming accepting toward marijuana use every single year.
States (and Washington, D.C. and Puerto Rico) that have already legalized medical marijuana, with some states gearing up for votes on recreational marijuana including Nevada, Maine, and California. Broadening acceptance of recreational marijuana could push half a dozen states to legalize it by the end of 2016.
The amount of recreational and medical marijuana sales in Colorado in 2015 alone. Meanwhile, Washington has brought in over $661 million in recreational sales since marijuana was legalized. Tax revenue from states where recreational marijuana is legal is already being used to fund education, improve infrastructure, and feed the homeless.
The estimated size of the 2015 hemp market, including CBD products ($65 million), foods ($90 million), and personal care products ($147 million). This marks an estimated 10% increase over 2014, and doesn’t even include sales data from big box retailers, which could more than double the estimate.
Percentage of physicians who support nationwide legalization of medical cannabis. Oncologists and Hematologists are the biggest supporters. As acceptance by the medical community snowballs, physicians are petitioning to open quality testing labs, marijuana clinics, and other businesses.
When many people think “cannabis”, they think of marijuana plants. And while marijuana and hemp plants are part of the same species, Cannabis sativa L., hemp is the food and fiber part of the plant, while marijuana is cultivated to maximize tetrahydrocannabinol (THC), the element that makes the user feel “high”. Both hemp and marijuana contain dozens of cannabinoids, naturally occurring chemical compounds, but it is cannabidiol (CBD), in particular that offers many health and therapeutic benefits – without the high. Hemp plants typically contain elevated levels of health-enhancing CBD, but by definition contain only trace levels of THC. This makes the hemp plant – gives hemp a lot of health potential, very attractive to those seeking an antioxidant-rich lifestyle, but not to recreational users. – without the side effects of marijuana.
In the late 1980s, scientists from the U.S. National Institutes of Health filed a patent attesting that cannabinoids not only have medicinal value, they might protect the brain against damage. Patent 6,630,507, often known as “Patent 507”, stated that cannabinoids, and in particular cannabidiol (CBD), could potentially stop cell death after a concussion, stroke, or other traumatic brain event. KannaLife Sciences, Inc.™, a Medical Marijuana, Inc. company that develops cannabinoid-based medicines for the brain, has secured the very first license to commercialize Patent 507. This means that KannaLife™ has the U.S. government’s green light to not only explore how non-psychotropic, antioxidant-rich CBD safeguards the brain from hepatic encephalopathy (HE) and chronic traumatic encephalopathy (CTE), but possibly offer it as a treatment for people with these neurodegenerative diseases.
On a federal level, it is illegal to grow cannabis in the United States. Compounds from cannabis, whether they come from hemp or marijuana, are considered schedule 1 drugs, which means the government believes these cannabinoids have no medical use. However, by growing our hemp outside the U.S. and producing and exporting CBD-rich, low (or no) THC products, we’re legally allowed to serve the U.S. market, as well as over 40 other countries. As a company, we are laying the framework for broader cannabis legalization, and we’re thrilled to play a primary role in positive change within the cannabis industry.
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.
* Cannabidiol (CBD) is a naturally-occurring constituent of the industrial hemp plant.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell and distribute hemp based products.